Celldex Therapeutics, Inc. – NASDAQ:CLDX
Founder-led company
Celldex Therapeutics stock price today
$20.58
-4.81
-18.94%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Celldex Therapeutics stock price monthly change
-36.21%
month
Celldex Therapeutics stock price quarterly change
-36.21%
quarter
Celldex Therapeutics stock price yearly change
-37.54%
year
Celldex Therapeutics key metrics
Market Cap | 1.63B |
Enterprise value | 1.44B |
P/E | -13.42 |
EV/Sales | 614.06 |
EV/EBITDA | -13.22 |
Price/Sales | 624.84 |
Price/Book | 4.51 |
PEG ratio | 0.28 |
EPS | -2.85 |
Revenue | 6.07M |
EBITDA | -153.56M |
Income | -144.87M |
Revenue Q/Q | -83.86% |
Revenue Y/Y | 92.76% |
Profit margin | -4765.59% |
Oper. margin | -4543.74% |
Gross margin | 0% |
EBIT margin | -4543.74% |
EBITDA margin | -2528.99% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCelldex Therapeutics stock price history
Celldex Therapeutics stock forecast
Celldex Therapeutics financial statements
Average Price Target
$62
Potential upside: 201.26%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 268K | -30.50M | -11381.34% |
|---|---|---|---|
| Sep 2023 | 1.51M | -38.26M | -2522.08% |
| Dec 2023 | 4.13M | -43.30M | -1048.32% |
| Mar 2024 | 156K | -32.80M | -21030.77% |
| Jun 2023 | 299311000 | 21.77M | 7.27% |
|---|---|---|---|
| Sep 2023 | 280256000 | 33.53M | 11.97% |
| Dec 2023 | 465627000 | 36.45M | 7.83% |
| Mar 2024 | 868847000 | 30.23M | 3.48% |
| Jun 2023 | -27.19M | 1.16M | 133K |
|---|---|---|---|
| Sep 2023 | -18.99M | 11.64M | 257K |
| Dec 2023 | -32.53M | -171.16M | 217.37M |
| Mar 2024 | -40.63M | -315.21M | 436.11M |
Celldex Therapeutics alternative data
| Aug 2023 | 148 |
|---|---|
| Sep 2023 | 148 |
| Oct 2023 | 148 |
| Nov 2023 | 148 |
| Dec 2023 | 148 |
| Jan 2024 | 148 |
| Feb 2024 | 148 |
| Mar 2024 | 160 |
| Apr 2024 | 160 |
| May 2024 | 160 |
| Jun 2024 | 160 |
| Jul 2024 | 160 |
Celldex Therapeutics other data
100.00%
0.00%
of CLDX is owned by hedge funds
157
-15
49.64M
+3.30M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 0 | 133169 |
| Jun 2024 | 0 | 220391 |
| Nov 2024 | 11500 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | MARUCCI ANTHONY S director, officer: PRESIDENT & .. | Common Stock | 11,500 | $26.82 | $308,430 | ||
Option | MARTIN SAMUEL BATES officer: SVP AND CFO | Incentive Stock Option (Right to Buy) | 16,968 | $10.38 | $176,128 | ||
Option | MARTIN SAMUEL BATES officer: SVP AND CFO | Common Stock | 16,968 | $10.38 | $176,128 | ||
Option | MARTIN SAMUEL BATES officer: SVP AND CFO | Common Stock | 3,201 | $9.02 | $28,863 | ||
Sale | MARTIN SAMUEL BATES officer: SVP AND CFO | Common Stock | 17,172 | $35.43 | $608,318 | ||
Option | MARTIN SAMUEL BATES officer: SVP AND CFO | Incentive Stock Option (Right to Buy) | 3,201 | $9.02 | $28,863 | ||
Option | CROWLEY ELIZABETH officer: SR. VP &.. | Incentive Stock Option (Right to Buy) | 30,000 | $10.38 | $311,400 | ||
Option | CROWLEY ELIZABETH officer: SR. VP &.. | Common Stock | 30,000 | $10.38 | $311,400 | ||
Sale | CROWLEY ELIZABETH officer: SR. VP &.. | Common Stock | 30,000 | $34.87 | $1,045,950 | ||
Option | YOUNG DIANE C. officer: SVP, CHIEF MEDICAL OFF.. | Common Stock | 15,000 | $2.71 | $40,650 |
| Patent |
|---|
Application Filling date: 22 Oct 2021 Issue date: 21 Jul 2022 |
Application Filling date: 27 Mar 2020 Issue date: 9 Jun 2022 |
Application Filling date: 4 Aug 2020 Issue date: 24 Feb 2022 |
Application Filling date: 18 Aug 2021 Issue date: 27 Jan 2022 |
Application Filling date: 4 Aug 2020 Issue date: 13 Jan 2022 |
Grant Filling date: 2 Jul 2015 Issue date: 23 Nov 2021 |
Grant Filling date: 26 Aug 2016 Issue date: 17 Aug 2021 |
Application Filling date: 17 Apr 2019 Issue date: 1 Jul 2021 |
Application Filling date: 8 Jan 2021 Issue date: 20 May 2021 |
Application Filling date: 16 Nov 2020 Issue date: 13 May 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2021 28 Feb 2022 | Q4 2021 Earnings Call Transcript |
| Q2 2020 7 Aug 2020 | Q2 2020 Earnings Call Transcript |
| Q2 2019 8 Aug 2019 | Q2 2019 Earnings Call Transcript |
| Q4 2018 8 Mar 2019 | Q4 2018 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Anthony S. Marucci M.B.A. (1962) Founder, Pres, Chief Executive Officer & Director | $1,060,000 |
| Dr. Tibor Keler (1959) Founder, Chief Scientific Officer & Executive Vice President | $654,910 |
| Dr. Margo Heath-Chiozzi M.D. (1957) Senior Vice President of Regulatory Affairs | $548,760 |
Mr. Sam Martin (1971) Senior Vice President, Chief Financial Officer, Sec. & Treasurer | $542,070 |
| Ms. Elizabeth Crowley (1972) Chief Product Devel. Officer & Senior Vice President | $507,240 |
MoneyShow's Best Investment Ideas For 2024: Part 3
MoneyShow's Best Investment Ideas For 2024: Part 2
Celldex: Mast Cell Disease Targeting Continues To Make Advancements In Clinic
Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU
Celldex Therapeutics: Revolutionizing Cancer Care With Innovative Immunotherapies
Celldex: Long List Of Failures, High Valuation, But Good Data Recently
Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement
Lantheus Holdings Rules The Medical Diagnostics Business World
Celldex: Pipeline Of Drug Candidates Is Worth A Look
-
What's the price of Celldex Therapeutics stock today?
One share of Celldex Therapeutics stock can currently be purchased for approximately $20.58.
-
When is Celldex Therapeutics's next earnings date?
Unfortunately, Celldex Therapeutics's (CLDX) next earnings date is currently unknown.
-
Does Celldex Therapeutics pay dividends?
No, Celldex Therapeutics does not pay dividends.
-
How much money does Celldex Therapeutics make?
Celldex Therapeutics has a market capitalization of 1.63B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 192.02% to 6.88M US dollars.
-
What is Celldex Therapeutics's stock symbol?
Celldex Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CLDX".
-
What is Celldex Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Celldex Therapeutics?
Shares of Celldex Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Celldex Therapeutics's key executives?
Celldex Therapeutics's management team includes the following people:
- Mr. Anthony S. Marucci M.B.A. Founder, Pres, Chief Executive Officer & Director(age: 63, pay: $1,060,000)
- Dr. Tibor Keler Founder, Chief Scientific Officer & Executive Vice President(age: 66, pay: $654,910)
- Dr. Margo Heath-Chiozzi M.D. Senior Vice President of Regulatory Affairs(age: 68, pay: $548,760)
- Mr. Sam Martin Senior Vice President, Chief Financial Officer, Sec. & Treasurer(age: 54, pay: $542,070)
- Ms. Elizabeth Crowley Chief Product Devel. Officer & Senior Vice President(age: 53, pay: $507,240)
-
Is Celldex Therapeutics founder-led company?
Yes, Celldex Therapeutics is a company led by its founders Mr. Anthony S. Marucci M.B.A. and Dr. Tibor Keler.
-
How many employees does Celldex Therapeutics have?
As Jul 2024, Celldex Therapeutics employs 160 workers.
-
When Celldex Therapeutics went public?
Celldex Therapeutics, Inc. is publicly traded company for more then 39 years since IPO on 15 May 1986.
-
What is Celldex Therapeutics's official website?
The official website for Celldex Therapeutics is celldex.com.
-
Where are Celldex Therapeutics's headquarters?
Celldex Therapeutics is headquartered at Perryville III Building, Hampton, NJ.
-
How can i contact Celldex Therapeutics?
Celldex Therapeutics's mailing address is Perryville III Building, Hampton, NJ and company can be reached via phone at +90 82007500.
-
What is Celldex Therapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Celldex Therapeutics in the last 12 months, the avarage price target is $62. The average price target represents a 201.26% change from the last price of $20.58.
Celldex Therapeutics company profile:
Celldex Therapeutics, Inc.
celldex.comExchange:
NASDAQ
Full time employees:
160
Industry:
Biotechnology
Sector:
Healthcare
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Perryville III Building
Hampton, NJ 08827
Hampton, NJ 08827
CIK: 0000744218
ISIN: US15117B2025
CUSIP: 15117B202
